Controversial Alzheimer’s drug could cost US $334B—nearly half of DoD budget – Ars Technica
Enlarge/ Pedestrians walk past Biogen Inc. headquarters in Cambridge, Massachusetts, on Monday, June 7, 2021. Biogen Inc. shares soared after its controversial Alzheimer’s disease therapy was approved by US regulators.
56 with 44 posters participating
Concern…
